The total operating income grew 50.5 per cent to Rs 2,881 cr during the quarter under review
Hyderabad, November 2014
“The quarterly performance has been satisfactory mainly on account of overall growth led by the US generics. Our business deliveries in Europe as well as other markets have been in line with our expectation. We are confident of sustaining this performance as we continue to focus on complex molecules and differentiated technology platforms for advanced markets,” said N Govindarajan, managing director of Aurobindo.
While the US contributed Rs 1,174.3 crore to Aurobindo’s sales in Q2 of FY15, as against Rs 730.8 crore in the corresponding quarter last year, Europe accounted for Rs 766.5 crore (Rs 170.6 crore in Q2 of FY14).
During the second quarter ended September 2014, Aurobindo filed two abbreviated new drug applications (ANDAs) and two drug master files (DMFs) in the US. Business Standard
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…
Nagpur, April 03, 2024: HCG Cancer Center Nagpur has launched a one-of-a-kind indigenous Asia`s first…